Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/29/2024 | $23.00 → $9.00 | Overweight → Neutral | JP Morgan |
| 9/8/2023 | $23.00 → $14.00 | Buy → Neutral | BofA Securities |
| 3/6/2023 | $35.00 → $34.00 | Neutral → Overweight | JP Morgan |
| 2/21/2023 | $41.00 → $53.00 | Neutral → Buy | Goldman |
| 1/27/2023 | $18.00 → $30.00 | Underweight → Equal-Weight | Morgan Stanley |
| 9/14/2022 | $40.00 | Outperform | SVB Leerink |
| 9/9/2022 | $15.00 | Underweight | Morgan Stanley |
| 3/3/2022 | $36.00 → $28.00 | Underperform → Neutral | Baird |
JP Morgan downgraded Vir Biotechnology from Overweight to Neutral and set a new price target of $9.00 from $23.00 previously
BofA Securities downgraded Vir Biotechnology from Buy to Neutral and set a new price target of $14.00 from $23.00 previously
JP Morgan upgraded Vir Biotechnology from Neutral to Overweight and set a new price target of $34.00 from $35.00 previously
– Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 – – Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts – – Combination well-tolerated: no treatment-related severe AEs, treatment-related discontinuations or ALT flares – – Following a recent FDA meeting, Phase 3 ECLIPSE registrational program to begin in the first half of 2025 – – New data presented at AASLD The Liver Meeting. Investor conference call November 19, 2024, at 5.15 a.m. PT / 8.15 a.m. ET – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced positive results from the SO
– Orphan designation in E.U. supports development of treatments for life-threatening or chronically debilitating conditions with significant unmet medical need – – Phase 2 SOLSTICE 24-week primary endpoint data for tobevibart and elebsiran in chronic hepatitis delta to be presented today at AASLD The Liver Meeting – – Positive opinion on E.U. orphan drug designation follows U.S. FDA fast track designation, highlighting growing recognition of the potential of tobevibart and elebsiran in chronic hepatitis delta – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has issued a positive opinion on t
– 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated interferon alfa – – No new safety concerns were identified, and treatment-emergent adverse events were generally mild to moderate – – Late-breaking oral presentation of MARCH Part B study results at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® – – Key functional cure data from 24-week follow-up expected in Q2 2025 – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart
SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)
SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)
SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
– Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 – – Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts – – Combination well-tolerated: no treatment-related severe AEs, treatment-related discontinuations or ALT flares – – Following a recent FDA meeting, Phase 3 ECLIPSE registrational program to begin in the first half of 2025 – – New data presented at AASLD The Liver Meeting. Investor conference call November 19, 2024, at 5.15 a.m. PT / 8.15 a.m. ET – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced positive results from the SO
– Orphan designation in E.U. supports development of treatments for life-threatening or chronically debilitating conditions with significant unmet medical need – – Phase 2 SOLSTICE 24-week primary endpoint data for tobevibart and elebsiran in chronic hepatitis delta to be presented today at AASLD The Liver Meeting – – Positive opinion on E.U. orphan drug designation follows U.S. FDA fast track designation, highlighting growing recognition of the potential of tobevibart and elebsiran in chronic hepatitis delta – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has issued a positive opinion on t
– 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated interferon alfa – – No new safety concerns were identified, and treatment-emergent adverse events were generally mild to moderate – – Late-breaking oral presentation of MARCH Part B study results at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® – – Key functional cure data from 24-week follow-up expected in Q2 2025 – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart
10-Q - Vir Biotechnology, Inc. (0001706431) (Filer)
8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
– Seasoned biotech executive brings decades of effective financial leadership to Vir – Vir Biotechnology Inc. (NASDAQ:VIR) today announced that Jason O'Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O'Byrne will join the Vir Executive Management Team and report directly to the company's Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA. Mr. O'Byrne is an accomplished executive with more than 20 years of experience in finance and operations. He is a recognized champion of financial discipline and brings demonstrated financial leadership in capital allocation and formation, corporate strategy, and operation
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer, effective November 6, 2023. Dr. Towne will be responsible for leading the Company's research function from basic research through scale-up manufacturing and the introduction of drug candidates to clinical trials. She will report to Vir's Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company's Executive Management Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231026830042/en/Jennifer Towne, Ph.D., appointed as Executive Vice President and
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application and granted Fast Track designation for the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection. Tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, are currently being evaluated in the Company's Phase 2 SOLSTICE hepatitis delta clinical trial, with complete 24-week treatment data on track to be reported in the fourth quarter.
Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Equal-Weight and raises the price target from $12 to $15.
On Wednesday, Vir Biotechnology Inc (NASDAQ:VIR) announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart and elebsiran for chronic hepatitis delta. Preliminary data from the Phase 2 trial show that treatment with tobevibart alone or combined with elebsiran was generally well tolerated. Participants achieved high virologic response rates at weeks 12 and 24, durable virologic response through 48 weeks, and high alanine transaminase (ALT) normalization rates. High levels of alanine aminotransferase (ALT) within a range of 1000-2000 IU/mL, is the hallmark of this stage of HBV disease. Similar virologic suppression and ALT normaliz